全文获取类型
| 收费全文 | 1181504篇 |
| 免费 | 80502篇 |
| 国内免费 | 1729篇 |
专业分类
| 耳鼻咽喉 | 16689篇 |
| 儿科学 | 33405篇 |
| 妇产科学 | 32150篇 |
| 基础医学 | 170598篇 |
| 口腔科学 | 34731篇 |
| 临床医学 | 101103篇 |
| 内科学 | 229290篇 |
| 皮肤病学 | 24646篇 |
| 神经病学 | 89818篇 |
| 特种医学 | 46522篇 |
| 外国民族医学 | 120篇 |
| 外科学 | 190662篇 |
| 综合类 | 24604篇 |
| 现状与发展 | 2篇 |
| 一般理论 | 380篇 |
| 预防医学 | 79181篇 |
| 眼科学 | 27433篇 |
| 药学 | 90248篇 |
| 3篇 | |
| 中国医学 | 2835篇 |
| 肿瘤学 | 69315篇 |
出版年
| 2018年 | 11968篇 |
| 2017年 | 9230篇 |
| 2016年 | 10341篇 |
| 2015年 | 11762篇 |
| 2014年 | 15888篇 |
| 2013年 | 23599篇 |
| 2012年 | 31660篇 |
| 2011年 | 32974篇 |
| 2010年 | 20078篇 |
| 2009年 | 19004篇 |
| 2008年 | 31892篇 |
| 2007年 | 33728篇 |
| 2006年 | 34304篇 |
| 2005年 | 32996篇 |
| 2004年 | 31908篇 |
| 2003年 | 30549篇 |
| 2002年 | 29711篇 |
| 2001年 | 65094篇 |
| 2000年 | 67210篇 |
| 1999年 | 55860篇 |
| 1998年 | 13208篇 |
| 1997年 | 11779篇 |
| 1996年 | 11743篇 |
| 1995年 | 11055篇 |
| 1994年 | 10197篇 |
| 1993年 | 9433篇 |
| 1992年 | 42119篇 |
| 1991年 | 40717篇 |
| 1990年 | 39505篇 |
| 1989年 | 38348篇 |
| 1988年 | 34983篇 |
| 1987年 | 34048篇 |
| 1986年 | 31875篇 |
| 1985年 | 30506篇 |
| 1984年 | 21804篇 |
| 1983年 | 18607篇 |
| 1982年 | 9892篇 |
| 1979年 | 19606篇 |
| 1978年 | 13419篇 |
| 1977年 | 11487篇 |
| 1976年 | 10088篇 |
| 1975年 | 11156篇 |
| 1974年 | 13451篇 |
| 1973年 | 12873篇 |
| 1972年 | 12153篇 |
| 1971年 | 11494篇 |
| 1970年 | 10970篇 |
| 1969年 | 10258篇 |
| 1968年 | 9492篇 |
| 1967年 | 8674篇 |
排序方式： 共有10000条查询结果，搜索用时 0 毫秒
101.
Oliver Sartor MD Daniel Heinrich MD Neil Mariados MD Maria José Méndez Vidal MD Daniel Keizman MD Camilla Thellenberg Karlsson MD Avivit Peer MD Giuseppe Procopio MD Stephen J. Frank MD Kalevi Pulkkanen MD Eli Rosenbaum MD Stefano Severi MD José Trigo MD Lucia Trandafir MD Volker Wagner MD Rui Li MS Luke T. Nordquist MD 《The Prostate》2019,79(14):1683-1691
102.
103.
A.B. Sanchez-Spitman J.J. Swen V.O. Dezentje D.J.A.R. Moes H. Gelderblom 《Expert review of clinical pharmacology》2019,12(6):523-536
Introduction: Tamoxifen dominates the anti-estrogenic therapy in the early and metastatic breast cancer setting. Tamoxifen has a complex metabolism, being mainly metabolized by CYP2D6 into its 30–100 times more potent metabolite, endoxifen. Recently, a phase I study in which endoxifen as an orally z-endoxifen hydrochloride has been successfully evaluated.
Areas covered: the principal pharmacogenetic and non-genetic differences in the pharmacology of tamoxifen and endoxifen are evaluated. To this end, references from PubMed, Embase or Web of Science, among others, were reviewed As non-genetic factors, important differences and similarities such age, or adherence to tamoxifen therapy are comprehensively illustrated. Additionally, since CYP2D6 genotypes are considered the main limitation of tamoxifen, many studies have investigated the association between the worsened clinical outcomes in patients with non-functional CYP2D6 genotypes. In this review, an overview of the research on this field is presented. Also, a summary describing the literature about individualizing tamoxifen therapy with endoxifen concentrations and its limitations is listed.
Expert opinion: z-endoxifen hydrochloride is only investigated in the metastatic setting, still more research is required before its place in therapeutics is known. Similarly, monitoring tamoxifen efficacy based on endoxifen concentrations might not be overall recommended due to the limited evidence available. 相似文献
104.
Éktova L. V. Goryunova O. V. Eremina V. A. Tikhonova N. I. Medvedeva L. A. 《Pharmaceutical Chemistry Journal》2019,53(7):604-609
Pharmaceutical Chemistry Journal - Use of formylindolylacetic acid as a reagent at the stage of preparing the glycosides of bis(indolyl)furan-2,5-diones and dioxane as solvent increased yields from... 相似文献
105.
106.
107.
Die Anaesthesiologie - Das Management des schwierigen Atemwegs ist eine präklinische Schlüsselqualifikation. Für Notärzte mit hohem Erfahrungsgrad im Atemwegsmanagement sind... 相似文献
108.
Hanna Lee Mary K. Tan Andrew T. Yan Paul Angaran Paul Dorian Claudia Bucci Jean C. Gregoire Alan D. Bell Martin S. Green Peter L. Gross Allan Skanes Charles R. Kerr L. Brent Mitchell Jafna L. Cox Vidal Essebag Brett Heilbron Krishnan Ramanathan Carl Fournier Shaun G. Goodman 《The Canadian journal of cardiology》2019,35(2):160-168
Background
Physicians treating nonvalvular atrial fibrillation (AF) assess stroke and bleeding risks when deciding on anticoagulation. The agreement between empirical and physician-estimated risks is unclear. Furthermore, the association between patient and physician sex and anticoagulation decision-making is uncertain.Methods
We pooled data from 2 national primary care physician chart audit databases of patients with AF (Facilitating Review and Education to Optimize Stroke Prevention in Atrial Fibrillation and Coordinated National Network to Engage Physicians in the Care and Treatment of Patients with Atrial Fibrillation Chart Audit) with a combined 1035 physicians (133 female, 902 male) and 10,927 patients (4567 female and 6360 male).Results
Male physicians underestimated stroke risk in female patients and overestimated risk in male patients. Female physicians estimated stroke risk well in female patients but underestimated the risk in male patients. Risk of bleeding was underestimated in all. Despite differences in risk assessment by physician and patient sex, > 90% of patients received anticoagulation across all subgroups. There was modest agreement between physician estimated and calculated (ie, CHADS2 score) stroke risk: Kappa scores were 0.41 (0.35-0.47) for female physicians and 0.34 (0.32-0.36) for male physicians.Conclusions
Our study is the first to examine the association between patient and physician sex influences and stroke and bleeding risk estimation in AF. Although there were differences in agreement between physician estimated stroke risk and calculated CHADS2 scores, these differences were small and unlikely to affect clinical practice; further, despite any perceived differences in the accuracy of risk assessment by sex, most patients received anticoagulation. 相似文献109.
C. Jacquet F. Goehringer E. Baux J.A. Conrad M.O. Ganne Devonec J.L. Schmutz G. Mathey H. Tronel T. Moulinet I. Chary-Valckenaere T. May C. Rabaud 《Médecine et maladies infectieuses》2019,49(2):112-120
Objective
The teaching hospital of Nancy, France, implemented a specific multidisciplinary care pathway (French acronym AMDPL) to improve the management of patients presenting with Lyme borreliosis (LB) suspicion. We aimed to assess the first year of activity of this care pathway.Patients and methods
We included all patients managed in the AMDPL pathway from November 1, 2016 to October 31, 2017. The first step was a dedicated Lyme disease consultation with an infectious disease specialist. Following this consultation, the LB diagnosis was either confirmed and adequate treatment was prescribed, or a differential diagnosis was established and patients received adequate management, or further investigations were required and patients were offered multidisciplinary management as part of a day hospitalization.Results
A total of 468 patients were included. LB diagnosis was confirmed in 15% of patients (69/468), 49% of patients received a differential diagnosis, and 26% (122/468) of patients had the LB diagnosis ruled out without receiving any other diagnosis.Conclusions
This is to our knowledge the first multidisciplinary center implemented in France for the management of patients presenting with LB suspicion related to polymorphous signs and symptoms. Several diagnoses could be confirmed or corrected, although some symptoms and complaints could not be explained. This cohort could improve our knowledge of LB and its differential diagnoses. 相似文献110.